Qing Wu , Jinmiao Liu , Weiyue Cao , Jiaxin Li , Huimin Li , Yuhan Jin , Zhitong Li , Xinyu Li , Wenying Sun , Lin Bai , Xinyuan Shen , Xiaochen Guo , Guiping Ren
{"title":"gm - csf佐剂的新城疫病毒载体二价疫苗增强了鸡对新城疫和传染性法氏囊病的双重免疫。","authors":"Qing Wu , Jinmiao Liu , Weiyue Cao , Jiaxin Li , Huimin Li , Yuhan Jin , Zhitong Li , Xinyu Li , Wenying Sun , Lin Bai , Xinyuan Shen , Xiaochen Guo , Guiping Ren","doi":"10.1016/j.vetimm.2025.111002","DOIUrl":null,"url":null,"abstract":"<div><div>Infectious bursal disease (IBD) and Newcastle disease (ND) are major infectious diseases that endanger poultry. Despite current vaccination efforts, both diseases still occur worldwide. We have developed bivalent vaccines capable of simultaneously preventing ND and IBD, which does not produce mutant IBDV. Using reverse genetics, we constructed a recombinant Newcastle disease virus (NDV) vector based on the common vaccine strain Clone30 to express the host-protective immunogen VP2L of the IBDV strain and chicken granulocyte-macrophage colony-stimulating factor (GM-CSF). The IBDV-encoded VP2L protein and chicken GM-CSF gene were inserted into different positions of the NDV full-length cDNA in various forms to achieve high-level expression. We successfully rescued the ND-AI bivalent vaccines (rClone30-VP2L(P/M)-GM-CSF(P/M), rClone30-VP2L(NP)-GM-CSF(P/M), rClone30-VP2L(P/M)-GM-CSF(NP) and rClone30-VP2L-IRES-GM-CSF(P/M)). The ND-AI bivalent vaccines maintained genetic stability after at least three consecutive passages in chicken embryos and was confirmed to express VP2L and GM-CSF proteins. The replication titers of the ND-AI bivalent vaccines in chicken embryos and cell cultures were comparable to those of the parental NDV strain rClone30. To assess the immunogenicity of the ND-AI bivalent vaccines, it was administered to 14-day-old commercial chicken chicks, and immune responses were continuously monitored for four weeks post-vaccination. By day 10 post-vaccination, the hemagglutination inhibition (HI) antibody titers of the recombinant NDV vaccine had far exceeded the theoretical protective threshold (4 log2) and remained at high levels for 28 days. Additionally, the levels of IBDV-specific antibodies in the ND-AI bivalent vaccines rapidly increased and remained at high titers for 14 days. Concurrently, the proliferation responses of B cells, CD4 + , and CD8 + T cells were enhanced, and the protein expression levels and mRNA transcription levels of inflammatory factors significantly increased. In summary, the ND-AI bivalent vaccines can stimulate the body to produce a stronger immune response, demonstrating its potential as a vaccine for IBD and ND. Additionally, the addition of GM-CSF can further enhance the immune response.</div></div>","PeriodicalId":23511,"journal":{"name":"Veterinary immunology and immunopathology","volume":"288 ","pages":"Article 111002"},"PeriodicalIF":1.4000,"publicationDate":"2025-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"GM-CSF-adjuvanted Newcastle disease virus-vectored bivalent vaccine elicits enhanced dual immunity against Newcastle disease and infectious bursal disease in chickens\",\"authors\":\"Qing Wu , Jinmiao Liu , Weiyue Cao , Jiaxin Li , Huimin Li , Yuhan Jin , Zhitong Li , Xinyu Li , Wenying Sun , Lin Bai , Xinyuan Shen , Xiaochen Guo , Guiping Ren\",\"doi\":\"10.1016/j.vetimm.2025.111002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Infectious bursal disease (IBD) and Newcastle disease (ND) are major infectious diseases that endanger poultry. Despite current vaccination efforts, both diseases still occur worldwide. We have developed bivalent vaccines capable of simultaneously preventing ND and IBD, which does not produce mutant IBDV. Using reverse genetics, we constructed a recombinant Newcastle disease virus (NDV) vector based on the common vaccine strain Clone30 to express the host-protective immunogen VP2L of the IBDV strain and chicken granulocyte-macrophage colony-stimulating factor (GM-CSF). The IBDV-encoded VP2L protein and chicken GM-CSF gene were inserted into different positions of the NDV full-length cDNA in various forms to achieve high-level expression. We successfully rescued the ND-AI bivalent vaccines (rClone30-VP2L(P/M)-GM-CSF(P/M), rClone30-VP2L(NP)-GM-CSF(P/M), rClone30-VP2L(P/M)-GM-CSF(NP) and rClone30-VP2L-IRES-GM-CSF(P/M)). The ND-AI bivalent vaccines maintained genetic stability after at least three consecutive passages in chicken embryos and was confirmed to express VP2L and GM-CSF proteins. The replication titers of the ND-AI bivalent vaccines in chicken embryos and cell cultures were comparable to those of the parental NDV strain rClone30. To assess the immunogenicity of the ND-AI bivalent vaccines, it was administered to 14-day-old commercial chicken chicks, and immune responses were continuously monitored for four weeks post-vaccination. By day 10 post-vaccination, the hemagglutination inhibition (HI) antibody titers of the recombinant NDV vaccine had far exceeded the theoretical protective threshold (4 log2) and remained at high levels for 28 days. Additionally, the levels of IBDV-specific antibodies in the ND-AI bivalent vaccines rapidly increased and remained at high titers for 14 days. Concurrently, the proliferation responses of B cells, CD4 + , and CD8 + T cells were enhanced, and the protein expression levels and mRNA transcription levels of inflammatory factors significantly increased. In summary, the ND-AI bivalent vaccines can stimulate the body to produce a stronger immune response, demonstrating its potential as a vaccine for IBD and ND. Additionally, the addition of GM-CSF can further enhance the immune response.</div></div>\",\"PeriodicalId\":23511,\"journal\":{\"name\":\"Veterinary immunology and immunopathology\",\"volume\":\"288 \",\"pages\":\"Article 111002\"},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2025-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Veterinary immunology and immunopathology\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0165242725001229\",\"RegionNum\":3,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Veterinary immunology and immunopathology","FirstCategoryId":"97","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0165242725001229","RegionNum":3,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
GM-CSF-adjuvanted Newcastle disease virus-vectored bivalent vaccine elicits enhanced dual immunity against Newcastle disease and infectious bursal disease in chickens
Infectious bursal disease (IBD) and Newcastle disease (ND) are major infectious diseases that endanger poultry. Despite current vaccination efforts, both diseases still occur worldwide. We have developed bivalent vaccines capable of simultaneously preventing ND and IBD, which does not produce mutant IBDV. Using reverse genetics, we constructed a recombinant Newcastle disease virus (NDV) vector based on the common vaccine strain Clone30 to express the host-protective immunogen VP2L of the IBDV strain and chicken granulocyte-macrophage colony-stimulating factor (GM-CSF). The IBDV-encoded VP2L protein and chicken GM-CSF gene were inserted into different positions of the NDV full-length cDNA in various forms to achieve high-level expression. We successfully rescued the ND-AI bivalent vaccines (rClone30-VP2L(P/M)-GM-CSF(P/M), rClone30-VP2L(NP)-GM-CSF(P/M), rClone30-VP2L(P/M)-GM-CSF(NP) and rClone30-VP2L-IRES-GM-CSF(P/M)). The ND-AI bivalent vaccines maintained genetic stability after at least three consecutive passages in chicken embryos and was confirmed to express VP2L and GM-CSF proteins. The replication titers of the ND-AI bivalent vaccines in chicken embryos and cell cultures were comparable to those of the parental NDV strain rClone30. To assess the immunogenicity of the ND-AI bivalent vaccines, it was administered to 14-day-old commercial chicken chicks, and immune responses were continuously monitored for four weeks post-vaccination. By day 10 post-vaccination, the hemagglutination inhibition (HI) antibody titers of the recombinant NDV vaccine had far exceeded the theoretical protective threshold (4 log2) and remained at high levels for 28 days. Additionally, the levels of IBDV-specific antibodies in the ND-AI bivalent vaccines rapidly increased and remained at high titers for 14 days. Concurrently, the proliferation responses of B cells, CD4 + , and CD8 + T cells were enhanced, and the protein expression levels and mRNA transcription levels of inflammatory factors significantly increased. In summary, the ND-AI bivalent vaccines can stimulate the body to produce a stronger immune response, demonstrating its potential as a vaccine for IBD and ND. Additionally, the addition of GM-CSF can further enhance the immune response.
期刊介绍:
The journal reports basic, comparative and clinical immunology as they pertain to the animal species designated here: livestock, poultry, and fish species that are major food animals and companion animals such as cats, dogs, horses and camels, and wildlife species that act as reservoirs for food, companion or human infectious diseases, or as models for human disease.
Rodent models of infectious diseases that are of importance in the animal species indicated above,when the disease requires a level of containment that is not readily available for larger animal experimentation (ABSL3), will be considered. Papers on rabbits, lizards, guinea pigs, badgers, armadillos, elephants, antelope, and buffalo will be reviewed if the research advances our fundamental understanding of immunology, or if they act as a reservoir of infectious disease for the primary animal species designated above, or for humans. Manuscripts employing other species will be reviewed if justified as fitting into the categories above.
The following topics are appropriate: biology of cells and mechanisms of the immune system, immunochemistry, immunodeficiencies, immunodiagnosis, immunogenetics, immunopathology, immunology of infectious disease and tumors, immunoprophylaxis including vaccine development and delivery, immunological aspects of pregnancy including passive immunity, autoimmuity, neuroimmunology, and transplanatation immunology. Manuscripts that describe new genes and development of tools such as monoclonal antibodies are also of interest when part of a larger biological study. Studies employing extracts or constituents (plant extracts, feed additives or microbiome) must be sufficiently defined to be reproduced in other laboratories and also provide evidence for possible mechanisms and not simply show an effect on the immune system.